A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Relapsed or Refractory Hematologic Malignancies

Interventions

DRUG

QLS2309

initial dose - MTD; QW; intravenous infusion

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY